This study compared weekly paclitaxel with or without trastuzumab beyond progression in patients with HER2-positive advanced gastric or GEJ adenocarcinoma refractory to fluoropyrimidine, platinum, and trastuzumab first-line therapy. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.